TY - JOUR
T1 - NMR structure of the viral peptide linked to the genome (VPg) of poliovirus
AU - Schein, Catherine H.
AU - Oezguen, Numan
AU - Volk, David E.
AU - Garimella, Ravindranath
AU - Paul, Aniko
AU - Braun, Werner
N1 - Funding Information:
This work was supported by grants from the U.S. Department of Energy (Grant Number DE-FG-00ER63041), the Sealy Center for Vaccine Development, and the National Institutes of Health to Eckard Wimmer (Grant number R37AI015122) and Werner Braun (R21AI55746). The NMR facilities of the Sealy Center for Structural Biology and Molecular Biophysics, which were funded by grants from the Sealy Foundation and Building funds from the NIH (Grant number 1CO6CA59098), were used in this project. We thank Lucy Lee for running the CD experiments.
PY - 2006/7
Y1 - 2006/7
N2 - VPgs are essential for replication of picornaviruses, which cause diseases such as poliomyelitis, foot and mouth disease, and the common cold. VPg in infected cells is covalently linked to the 5′ end of the viral RNA, or, in a uridylylated form, free in the cytoplasm. We show here the first solution structure for a picornaviral VPg, that of the 22-residue peptide from poliovirus serotype 1. VPg in buffer is inherently flexible, but a single conformer was obtained by adding trimethylamine N-oxide (TMAO). TMAO had only minor effects on the TOCSY spectrum. However, it increased the amount of structured peptide, as indicated by more peaks in the NOESY spectrum and an up to 300% increase in the ratio of normalized NOE cross peak intensities to that in buffer. The data for VPg in TMAO yielded a well defined structure bundle with 0.6 Å RMSD (versus 6.6 Å in buffer alone), with 10-30 unambiguous constraints per residue. The structure consists of a large loop region from residues 1 to 14, from which the reactive tyrosinate projects outward, and a C-terminal helix from residues 18 to 21 that aligns the sidechains of conserved residues on one face. The structure has a stable docking position at an area on the poliovirus polymerase crystal structure identified as a VPg binding site by mutagenesis studies. Further, UTP and ATP dock in a base-specific manner to the reactive face of VPg, held in place by residues conserved in all picornavirus VPgs.
AB - VPgs are essential for replication of picornaviruses, which cause diseases such as poliomyelitis, foot and mouth disease, and the common cold. VPg in infected cells is covalently linked to the 5′ end of the viral RNA, or, in a uridylylated form, free in the cytoplasm. We show here the first solution structure for a picornaviral VPg, that of the 22-residue peptide from poliovirus serotype 1. VPg in buffer is inherently flexible, but a single conformer was obtained by adding trimethylamine N-oxide (TMAO). TMAO had only minor effects on the TOCSY spectrum. However, it increased the amount of structured peptide, as indicated by more peaks in the NOESY spectrum and an up to 300% increase in the ratio of normalized NOE cross peak intensities to that in buffer. The data for VPg in TMAO yielded a well defined structure bundle with 0.6 Å RMSD (versus 6.6 Å in buffer alone), with 10-30 unambiguous constraints per residue. The structure consists of a large loop region from residues 1 to 14, from which the reactive tyrosinate projects outward, and a C-terminal helix from residues 18 to 21 that aligns the sidechains of conserved residues on one face. The structure has a stable docking position at an area on the poliovirus polymerase crystal structure identified as a VPg binding site by mutagenesis studies. Further, UTP and ATP dock in a base-specific manner to the reactive face of VPg, held in place by residues conserved in all picornavirus VPgs.
KW - Circular dichroism
KW - Picornavirus
KW - Polymerase interaction
KW - Post-translational modification
KW - Solvent stabilization
KW - Trimethylamine N-oxide (TMAO)
KW - Uridylylation
KW - Viral replication
UR - http://www.scopus.com/inward/record.url?scp=33744984790&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33744984790&partnerID=8YFLogxK
U2 - 10.1016/j.peptides.2006.01.018
DO - 10.1016/j.peptides.2006.01.018
M3 - Article
C2 - 16540201
AN - SCOPUS:33744984790
SN - 0196-9781
VL - 27
SP - 1676
EP - 1684
JO - Peptides
JF - Peptides
IS - 7
ER -